NCT02071888 - Study of the Glutaminase Inhibitor CB-839 in Hematological Tumors | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 28, 2014

Primary Completion Date

April 30, 2016

Study Completion Date

April 30, 2016

Conditions

Non-Hodgkin's Lymphoma (NHL)Multiple MyelomaWaldenstrom's Macroglobulinemia (WM)Other B-cell NHL Subtypes, Including WMT-cell NHL

Interventions

DRUG

CB-839

Glutaminase inhibitor

DRUG

CB-839 and low dose dexamethasone

DRUG

CB-839, pomalidomide, and low dose dexamethasone

Trial Locations (7)

Weill Cornell Medical College, New York

University of Pennsylvania, Abramson Cancer Center, Philadelphia

Winship Cancer Institute of Emory School of Medicine, Atlanta

Tennessee Oncology, PLLC, Nashville

Colorado Blood Cancer Institute, Denver

Mayo Clinic, Scottsdale

John Theruer Cancer Center at Hackensack University Medical Center, Hackensack